GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kezar Life Sciences Inc (NAS:KZR) » Definitions » Cyclically Adjusted FCF per Share

Kezar Life Sciences (Kezar Life Sciences) Cyclically Adjusted FCF per Share : $0.00 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Kezar Life Sciences Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Kezar Life Sciences's adjusted free cash flow per share data for the fiscal year that ended in Dec. 2023 was $-1.150. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.00 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-04-28), Kezar Life Sciences's current stock price is $ 0.8049. Kezar Life Sciences's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec. 2023 was $0.00. Kezar Life Sciences's Cyclically Adjusted Price-to-FCF of today is .


Kezar Life Sciences Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Kezar Life Sciences's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kezar Life Sciences Cyclically Adjusted FCF per Share Chart

Kezar Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial - - - - -

Kezar Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kezar Life Sciences's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Kezar Life Sciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kezar Life Sciences's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kezar Life Sciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Kezar Life Sciences's Cyclically Adjusted Price-to-FCF falls into.



Kezar Life Sciences Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kezar Life Sciences's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.15/129.4194*129.4194
=-1.150

Current CPI (Dec. 2023) = 129.4194.

Kezar Life Sciences does not have a history long enough to calculate Cyclically Adjusted FCF per Share. Therefore GuruFocus does not calculate it.


Kezar Life Sciences  (NAS:KZR) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Kezar Life Sciences Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Kezar Life Sciences's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Kezar Life Sciences (Kezar Life Sciences) Business Description

Industry
Traded in Other Exchanges
Address
4000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as KZR-616, and the protein secretion program.
Executives
Morningside Venture Investments Ltd 10 percent owner MCCARTHY LEGAL SERVICES, 1188 CENTRE STREET, NEWTON CENTRE MA 02459
Nicholas Michael Mordwinkin officer: Chief Business Officer C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Wallace Courtney director C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Micki Klearman director C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Equal Talent Investments Ltd 10 percent owner THC MANAGEMENT SERVICES S.A.M. 2ND FLOOR, LE PRINCE DE GALLES 3-5 AVE DE CITRONNIE, MONTE CARLO O9 98000
Noreen Henig officer: Chief Medical Officer C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
John Franklin Fowler director, officer: CEO C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Christopher J. Kirk director, officer: President and CSO C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Marc Belsky officer: Chief Financial Officer C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Vassiliki Economides officer: SVP, Strategy & External Aff. C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Elizabeth Garner director 101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Gp, Llc 10 percent owner 100 HIGH STREET, SUITE 1105, BOSTON DC 02110
Bay City Capital Llc 10 percent owner 750 BATTERY STREET STE 400, SAN FRANCISCO CA 94111

Kezar Life Sciences (Kezar Life Sciences) Headlines

From GuruFocus

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

By Business Wire Business Wire 02-06-2023

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

By Business Wire Business Wire 06-09-2023